BeOne Medicines Edges Lower as Insider Sales Mount Before Q3 Print

ONC heads into its November 5 earnings release with a notable convergence of insider selling, activist stake reduction, and a stock that has slipped nearly 2% on the week to $370.33.

Short interest at BeOne is modest and not the story here. At 1.6% of the free float, around 1.79 million shares, it has nudged up roughly 22% over the past month in share terms, but from a low base. Borrow conditions confirm the lack of short-side urgency: the cost to borrow is just 0.57%, down 4.6% on the week, and availability is extraordinarily loose at 3,761%, meaning the lending pool has far more supply than demand from short sellers. The ORTEX short score of 35.4 is stable and unremarkable.

The ownership picture is more interesting. Director Wang Xiaodong filed a series of option exercises and open-market sales on October 27, all conducted under a pre-arranged 10b5-1 plan. Sales across multiple tranches totalled roughly $6.9 million in gross proceeds at prices ranging from $355 to $365 per share. Planned sales under a 10b5-1 programme carry less signal than discretionary disposals, but the 90-day net insider position across the register has reached negative 194,835 shares, representing roughly $69.6 million in net sales. That is a meaningful directional tilt heading into a print. Separately, HHLR Advisors filed a Schedule 13D amendment in May 2025 disclosing a reduction from 6.7% to 4.9% of the class, and Julian C. Baker, also on the 13D register, trimmed from 8.0% to 7.8% in a September 2026 amendment. Both are activist-flagged holders; their disclosed reductions are worth noting, though stakes are as last disclosed around the 5% threshold and positions may have moved further without triggering another filing.

The Street remains firmly constructive on BeOne despite the insider activity. JP Morgan raised its target to $445 from $425 in early October, maintaining Overweight, and RBC Capital followed with a lift to $459 from $450. The consensus mean target is $436.46, implying roughly 18% upside to current prices. The bull case centres on Brukinsa's commercial trajectory, with projected peak sales near $7.1 billion by 2034, and the emerging sonrotoclax data. Bears flag clinical trial risk, pipeline cash burn, and geopolitical exposure given BeOne's China-linked structure. Valuation is not cheap: the PE multiple is 37.3, with EV/EBITDA at 24.8, both having compressed slightly over the past 30 days. The earnings yield factor ranks in the 69th percentile and the EPS surprise rank is 77th, reflecting a track record of beating estimates, though the ev_ebit score of just 18 is a reminder that the company trades on growth hopes rather than current earnings power.

Retail attention has picked up sharply ahead of the release. The ORTEX Wikipedia views signal carries a z-score of 4.8 against BeOne's own 90-day history, one of the more elevated readings in the dataset, suggesting a burst of retail interest in the name around the upcoming print.

Among correlated peers, HALO added 4.2% on the week while VRDN rose 10.3%. ORIC was the notable laggard, down nearly 30% on the week. BeOne's own 1.9% weekly decline underperformed the peer median by about 1.7 percentage points, though the prior three earnings releases all produced negative one-day moves averaging around 2%, so the market appears to have some caution already priced into the tape. The November 5 print and any pipeline update on sonrotoclax are the events that will determine how much of the Street's optimism holds.